TABLE 4.
Effects of the expression of pknB on quinolone susceptibility
| Strain (plasmid)a | Genotype expression levelb | MIC (μg/ml)
|
|||
|---|---|---|---|---|---|
| Nor- floxacin | Cipro- floxacin | Moxi- floxacin | Spar- floxacin | ||
| RN6390 | rsbU − | 0.5 | 0.25 | 0.03 | 0.06 |
| SH1000 | rsbU+ | 0.5 | 0.5 | 0.03 | 0.06 |
| RN6390 (pSK950) | rsbU− | 0.5 | 0.25 | 0.03 | 0.06 |
| SH1000 (pSK950) | rsbU+ | 0.5 | 0.5 | 0.03 | 0.06 |
| RN6390 (pQT16) | rsbU−; pknB+++ | 2 | 1 | 0.03 | 0.06 |
| SH1000 (pQT16) | rsbU+; pknB+++ | 2 | 2 | 0.03 | 0.06 |
a
Strains harboring plasmid pSK950 or pQT16 were grown in the presence of tetracycline (5 μg/ml).
b
−, negative; +, positive; +++, overexpression.